6-Oxo-PGF(1α) and 8-epi-PCF(2α) in human atherosclerotic vascular tissue

Prostaglandins Leukotrienes and Essential Fatty Acids

Volumn 60, Issue 2, 1999, Pages 129-134

  Oguogho, A ^a   Karanikas, G ^a   Kritz, H ^b   Riehs, G ^a   Wagner, O ^c   Sinzinger, H ^a,d  

^a UNIVERSITY OF VIENNA   (Austria)

^b Rehabilitation Center   (Austria)

^c KRANKENHAUS DER BARMHERZIGEN BRÜDER   (Austria)

^d WAARG   (Austria)

Author keywords

[No Author keywords available]

Indexed keywords

6 OXOPROSTAGLANDIN F1 ALPHA; 8 ISOPROSTAGLANDIN F2 ALPHA; PROSTACYCLIN; 8 EPI PROSTAGLANDIN F2ALPHA; 8-EPI-PROSTAGLANDIN F2ALPHA; DRUG DERIVATIVE; ISOPROSTANE DERIVATIVE; PROSTAGLANDIN F2 ALPHA;

ADULT; AGED; ARTERY WALL; ARTICLE; ATHEROSCLEROSIS; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN TISSUE; HYPERLIPIDEMIA; HYPERTENSION; LIPID PEROXIDATION; MALE; NORMAL HUMAN; PRIORITY JOURNAL; SMOKING; VASCULAR TISSUE; AGE; ARTERIOSCLEROSIS; BLOOD VESSEL; COMPARATIVE STUDY; IMMUNOASSAY; IN VITRO STUDY; METABOLISM; MIDDLE AGED;

6-KETOPROSTAGLANDIN F1 ALPHA; AGE FACTORS; AGED; ARTERIOSCLEROSIS; BLOOD VESSELS; DINOPROST; EPOPROSTENOL; F2-ISOPROSTANES; FEMALE; HUMANS; IMMUNOASSAY; MALE; MIDDLE AGED;

EID: 0032588363     PISSN: 09523278     EISSN: None     Source Type: Journal    
DOI: 10.1054/plef.1998.0019     Document Type: Article

References (26)

1. 2-isoprostanes) in smokers. Smoking as a cause of oxidative damage. New Engl J Med 1995; 332: 1198-1203.
2. Alessandrini A., Giabattoni P., Cipolione G. et al. Enhanced isoprostane biosynthesis in type IIa hypercholesterolemia. Circulation 1996; 94 Suppl: 85.
3. 2-isoprostanes in vivo: Indices of oxidant stress in atherosclerotic disease. Vasc Biol 1997; 17: 2309-2315.
4. Leitinger N., Oguogho A., Pirich C., Sinzinger H. Prostaglandins of the E-series show different effects on in-vitro oxidation of LDL. Atherosclerosis 1994; 109: 44-45.
5. 2α. Brit J Pharm 1996; 119: 1276-1280.
6. 2α: An index of oxidative stress in vivo. Circulation 1996; 94: 277.
7. Sinzinger H., Feigl W., Silberbauer K. Prostacyclin generation in atherosclerotic arteries. Lancet 1979; II: 442-444.
8. 2-like compounds are produced in vivo in human by a non-cyclooxygenase free radical-catalyzed mechanism. Proc Natl Acad Sci USA 1990; 87: 9383-9387.
9. Morrow J. D., Awad J. A., Wu A., Zackert W. E., Daniel V. C., Roberts II L. J. Nonenzymatic free radical-catalyzed generation of thromboxane-like compounds (isothromboxanes) in vivo. Biol Chem 1996; 217: 23185-23190.
10. 2-isoprostane) metabolites in urin and plasma. J Biol Chem 1993; 268: 4161-416 9.
11. 2α in the rabbit. Prostaglandins Leukot Essent Fatty Acids 1997; 57: 266.
12. 2-isoprostanes during oxidative modification of low-density lipoprotein. Biochem Biophys Res Commun 1994; 200: 338-343.
13. 2-isoprostanes during oxidation of human low-density lipoproteins and plasma by peroxynitrite. Circ Res 1995; 77: 335-341.
14. 2α in the rat. J Clin Invest 1992; 90: 136-141.
15. 2/prostaglandin endoperoxide receptors in porcine carotid arteries. Biochem Res Commun 1996; 225: 915-923.
16. 2α, a potent agonist of the vascular thromboxane/endoperoxide receptor, is a platelet thromboxane/ endoperoxide antagonist. Prostaglandins 1992; 44: 155-163.
17. 2α in rabbit lung in situ. Am J Physiol 1992; 263: H660-H664.
18. 2α on the contractility of the human myometrium in vitro. Europ J Pharmacol 1995; 285: 151-158.
19. 2 isoprostane. Biochem Biophys Res Commun 1993; 195: 507-515.
20. 2-isoprostane in vascular smooth muscle cells by elevated glucose and growth factors. Am J Physiol 1996; 271: 159-165.
21. Leitinger N., Blazek I., Sinzinger H. The influence of isoprostanes on ADP-induced platelet aggregation and cyclic AMP-generation in human platelets. Thromb Res 1997; 86: 337-342.
22. 2. Adv Prostagandin Thromboxane Leukot Res 1995; 23: 237-239.
23. Oguogho A., Kritz H., Sinzinger H. Einmaliges Passivrauchen induziert keine meßbare oxidation der low-density lipoproteine. Wr Klin Wschr 1996; 108: 589-592.
24. Ougogho A. The role of low-density lipoprotein in atherosclerosis: Possible protective effects of eicosanoids, calcium antagonists and acetylsalicylic acid. Series Eicosanoids and Fatty Acids, Thesis, Facultas Publ., Vienna, 1996.
25. Reilly M., Delanty N., Lawson J. A., Fitzgerald G. A. Modulation of oxidant stress in vivo in chronic cigarette smokers. Circulation 1996; 94: 19-25.
26. 2-isoprostanes, are present in increased amount in human atherosclerotic lesions. Arterioscler Thromb Vasc Biol 1997; 17: 3236-3241.